头颈癌治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

2023年，全球头颈癌治疗市场价值为18亿美元，预计2024年至2032年复合年增长率为8.9%。 GLOBOCAN 的统计数据强调头颈癌是全球最常见的癌症之一。此外，烟草和酒精的消费量不断增加，这两种头颈癌的重要风险因素，将进一步推动该产业的成长。

随着个体年龄的增长，他们对基因突变的易感性会增加，而身体的 DNA 修復机制会减弱，从而增加癌症风险。这种自然老化轨迹表明，不断扩大的老年人口可能会导致癌症病例激增。美国癌症协会指出，大约 57% 的新诊断癌症和 75% 的癌症相关死亡发生在 65 岁及以上的人群中。值得注意的是，这个年龄层是成长最快的部分，尤其是在美国等已开发国家

头颈癌盛行率的上升极大地推动了市场的发展。例如，美国国家癌症研究所预计，到 2024 年，美国将有 71,000 人被诊断出患有咽、喉或口腔癌症。 HPV，尤其是第 16 型，对口咽癌，尤其是影响扁桃体和舌根的口咽癌构成显着风险。 HPV 相关感染的增加与这些癌症的增加有关。

整个产业分为治疗类型、给药途径、配销通路和地区。

按治疗类型细分的市场包括化疗、免疫疗法、标靶治疗等。 2023年，免疫治疗领域引领市场，占9.727亿美元。免疫疗法成为头颈癌患者的希望灯塔，尤其是那些处于晚期或復发阶段的患者。透过利用人体的免疫系统来识别和对抗癌细胞，免疫疗法为手术、放疗和化疗等传统治疗提供了一种引人注目的替代方案。

头颈癌治疗的给药途径包括注射、口服方法等。 2023 年，注射剂占了 57.4% 的主导份额。这些药物针对癌症或免疫细胞上的特定蛋白质，需要直接血流给药以获得最佳疗效。

北美引领全球头颈癌治疗市场，2023 年收入为6.614 亿美元，预计到2032 年将达到14 亿美元。推出和实施。此外，患者意识的提高以及获得尖端治疗方案的机会巩固了北美在行业格局中的地位。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 头颈癌发生率增加
    • 老年人口基数不断增加
    • 加大研发投入以开发新药
    • 支持性报销政策和疾病意识的提高
  • 产业陷阱与挑战
    • 治疗费用高
    • 副作用和安全问题
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

• 主要趋势
• 化疗
• 免疫疗法
• 标靶治疗
• 其他疗法

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

• 主要趋势
• 可注射
• 口服
• 其他给药途径

第 7 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售和专业药房
• 网路药房

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bristol-Myers Squibb Company (BMS)
• C.H. Boehringer Sohn AG and Co. KG
• Clinigen Group plc.
• Coherus BioSciences
• Cumberland Pharmaceuticals, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Merck and Co., Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

The Global Head and Neck Cancer Therapeutics Market was valued at USD 1.8 billion in 2023 and is projected to grow at a CAGR of 8.9% from 2024 to 2032. The primary driver of this market growth is the rising prevalence of head and neck cancer. Statistics from GLOBOCAN highlight head and neck cancer as one of the most prevalent cancers worldwide. Furthermore, the escalating consumption of tobacco and alcohol, both significant risk factors for head and neck cancers, is poised to further propel the industry growth.

As individuals age, their susceptibility to genetic mutations heightens, and the body's DNA repair mechanisms wane, amplifying cancer risks. This natural aging trajectory indicates that an expanding elderly demographic will likely see a surge in cancer cases. The American Cancer Society notes that approximately 57% of new cancer diagnoses and 75% of cancer-related deaths are in individuals aged 65 years and older. Notably, this age bracket is the fastest growing segment, especially in developed nations like the U.S.

The rising prevalence of head and neck cancer significantly propels the market. For instance, in 2024, the National Cancer Institute projects that 71,000 individuals in the U.S. will be diagnosed with cancers of the pharynx, larynx, or oral cavity. HPV, especially type 16, poses a notable risk for oropharyngeal cancers, particularly those impacting the tonsils and tongue's base. An uptick in HPV-related infections correlates with a rise in these cancers.

The overall industry is divided into therapy type, route of administration, distribution channel, and region.

The market segments by therapy type include chemotherapy, immunotherapy, targeted therapy, and others. In 2023, the immunotherapy segment led the market, accounting for USD 972.7 million. Immunotherapy emerges as a beacon of hope for head and neck cancer patients, especially those grappling with advanced or recurrent stages. By harnessing the body's immune system to identify and combat cancer cells, immunotherapy presents a compelling alternative to conventional treatments, such as surgery, radiation, and chemotherapy.

Routes of administration for head and neck cancer therapeutics include injectables, oral methods, and others. The injectables commanded a dominant 57.4% share in 2023. Leading immunotherapy agents for head and neck cancer, including Pembrolizumab (Keytruda) and Nivolumab (Opdivo), are primarily delivered via IV injectables. These agents target specific proteins on cancer or immune cells, necessitating direct bloodstream administration for optimal efficacy.

North America led the global head and neck cancer therapeutics market, generated USD 661.4 million in revenue in 2023 with projections to hit USD 1.4 billion by 2032. This regional leadership is attributed to a robust healthcare infrastructure and regulatory frameworks that fast-track the introduction and acceptance of innovative therapies. Furthermore, increased patient awareness coupled with access to cutting-edge treatment options cements North America's position in the industry landscape.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of head and neck cancer
    • 3.2.1.2 Growing geriatric population base
    • 3.2.1.3 Rising investment in R&D to develop new drugs
    • 3.2.1.4 Supportive reimbursement policies and rising awareness about disease
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Chemotherapy
• 5.3 Immunotherapy
• 5.4 Targeted therapy
• 5.5 Other therapies

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Injectable
• 6.3 Oral
• 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail and specialty pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 AstraZeneca plc
• 9.4 Bristol-Myers Squibb Company (BMS)
• 9.5 C.H. Boehringer Sohn AG and Co. KG
• 9.6 Clinigen Group plc.
• 9.7 Coherus BioSciences
• 9.8 Cumberland Pharmaceuticals, Inc.
• 9.9 Eli Lilly and Company
• 9.10 F. Hoffmann-La Roche Ltd.
• 9.11 GSK plc
• 9.12 Merck and Co., Inc.
• 9.13 Sanofi S.A.
• 9.14 Takeda Pharmaceutical Company Limited
• 9.15 Teva Pharmaceutical Industries Ltd.